Thursday, October 22, 2026

Interview with Dr. Roberto Cesar Leite. October 22,2026




Dr. Roberto Cesar Leite
Interview conducted by Dr. Donato Pérez García
Two decades of IPT in Brazil, international exchange, and a friendship between colleagues

Introduction

Some conversations happen out of duty, and others out of affection. This is one of the latter. For many years, Dr. Roberto Cesar Leite and I have shared more than an interest in Insulin Potentiation Therapy (IPT): we have shared classrooms, journeys, conferences and, above all, a friendship that has crossed borders.

Roberto is a physician, a specialist in Medical Nutrology, a doctor in Naturopathy and Nutrition, and coordinator of INTEGRA / SPES Centro de Ensino e Especialização em Saúde Integrada in Brazil. For close to twenty years he has been one of the leading promoters of IPT in his country.

I wanted to conduct this interview to record his journey in his own words, and also to keep, in one place, the memory of what we have lived together as colleagues and friends. What follows is our conversation.

— Dr. Donato Pérez García
The beginnings: training and integrative medicine

Dr. Donato Pérez García: Roberto, dear friend, thank you for agreeing to this conversation. Let's start at the beginning. How did your path in medicine begin?

Dr. Roberto Cesar Leite: Thank you, Donato. It is a great pleasure to do this with you. I graduated in Medicine from the Faculdade Evangélica de Medicina do Paraná in 1986. Very early on I understood that practicing medicine demands constant updating, analytical ability and a willingness to explore different therapeutic perspectives. Medicine does not end with the degree; that is where it begins.

DPG: And you did not stand still. A very broad education followed.
RCL: That's right. I expanded my training with studies in Homeopathy, Acupuncture and Medical Nutrology. In 2003 I earned a doctorate in Naturopathy and Nutrition from Bircham International University in Spain. Each stage gave me different tools to better understand human health.

DPG: What drew you to integrative medicine?
RCL: I was, and still am, interested in the relationships between metabolism, nutrition, physiological processes and complementary therapeutic approaches. Over time, that interest also led me to invest in training professionals and producing educational materials.

DPG: I have always known you as someone who thinks out loud with others, not just for himself.
RCL: I firmly believe that the evolution of medicine depends not only on accumulated experience. It depends on the ability to share knowledge, to dialogue with other professionals and to critically examine the possibilities and limitations of each approach. It was in that context that IPT began to take on an important place in my professional life.
Encountering IPT in Brazil

DPG: Let's talk about IPT. When and how did you come to it?
RCL: About twenty years ago I began working with IPT in Brazil. At that time, spreading it was a real challenge. It required dedication to studying its foundations, contact with experienced professionals and a willingness to go deeper into knowledge that was still little known among many Brazilian physicians.

DPG: What sparked your curiosity?
RCL: I wanted to understand the relationships between insulin, cellular metabolism and the hypotheses behind its use in certain therapeutic contexts. From that interest, I began devoting part of my work to studying IPT, to discussing its protocols and to seeking opportunities for Brazilian professionals to access serious information on the subject.

DPG: I remember you always insisted on knowing the history, not just the technique.
RCL: Because passing on specialized knowledge takes much more than presenting a procedure. You need to know its history, the people who contributed to its development, study its physiological foundations and critically follow the research on its safety and efficacy.
And that is where another important challenge appeared: bringing Brazilian physicians closer to international experience, creating opportunities to learn directly from those who already had years of practice. That initiative became one of the most meaningful dimensions of my journey with IPT.
Our collaboration: a bridge between Mexico and Brazil

DPG: This is where I come into the story. How do you remember the start of our collaboration?
RCL: With great affection, Donato. Among all the professional relationships I built along the way, ours holds a special place. You belong to the third generation of a family historically linked to the development and transmission of IPT. The history of the technique goes back to the work of your grandfather, Dr. Donato Pérez García, Donato I, and continued in the generations that followed. That family history is part of the story I try to preserve and share through teaching.

DPG: And you were determined to bring me to Brazil.
RCL: (Laughs) Yes, I was determined. I recognized the value of direct contact with someone who knew the evolution of IPT from the inside and had international experience. That is why I worked to bring you to Brazil to teach courses on the technique.

DPG: What did those courses mean to you?
RCL: They had a very special meaning. Besides offering learning, they brought Brazilian physicians closer to an international experience that until then had been hard for many of them to reach. Bringing a professional from abroad takes initiative, organization and the conviction that training grows stronger when different experiences are in dialogue. That was the spirit in which we did it.

DPG: And from there something more than a working relationship was born.
RCL: Exactly. Over the years our relationship went beyond the strictly professional and became a friendship built around a love of knowledge, the exchange of experiences and a dedication to teaching. For me it represents the meeting of two professionals, but also a bridge between two countries so that knowledge can flow.

DPG: For me too, Roberto. Few people understand my family's history with the respect you have shown it.
Two encounters we treasure: Austria 2012 and Curitiba 2024

DPG: There are two moments we always bring up when we see each other. The first is Austria.
RCL: Austria, 2012. It was a milestone in our journey. That meeting was captured in photographs that we later included in the IPT educational material developed at SPES. That photo is, for me, a very meaningful memory of our exchange and of the lasting ties we built around the study of the technique.

DPG: What do these international encounters give you?
RCL: They let you learn other perspectives, share experiences and better understand the historical development of a therapeutic approach. But above all, they remind me how important human relationships are in building knowledge. Medicine is an activity deeply shaped by the meeting of people. Many educational initiatives are born precisely from trust, friendship and the desire to share what we have learned.

DPG: Twelve years later we met again in your homeland.
RCL: Yes, at the 1st International Congress of Integrative Medicine Applied to Oncology, in Curitiba, November 14 to 16, 2024. The congress brought together professionals from different fields, with discussions on integrative medicine and exchange between Brazilian specialists and international guests.
Being by your side there again symbolized the continuity of our relationship. Austria and Curitiba are two different moments, but united by the same friendship, the same collaboration and the same interest in the study of IPT. That meeting was also documented in SPES's institutional material.

DPG: Why does organizing spaces like this matter so much to you?
RCL: Because they create learning environments and encourage dialogue among professionals. A congress of that size reflects a concern that has always been with me: that knowledge can be presented, discussed and subjected to critical analysis, respecting the complexity of clinical challenges.

Year &Place.What we remember
2024:Curitiba, Brazil
1st International Congress of Integrative Medicine Applied to Oncology (November 14–16)

2012: Austria
International meeting, captured in photographs in SPES educational material

Over the years: Brazil
IPT courses taught by Dr. Donato Pérez García
Science, responsibility and teaching

DPG: You have always been very clear about IPT's place in clinical practice. How would you explain it today?
RCL: IPT starts from hypotheses about the action of insulin and cellular metabolism, and proposes using it to enhance the action of certain medications in specific contexts. But the proposed mechanisms and clinical results must be analyzed according to the quality of the evidence available for each indication.
This is especially important in oncology. A practitioner's experience can help formulate questions and guide research, but on its own it does not prove efficacy or establish causality.

DPG: What do you consider essential in that debate?
RCL: Analyzing the physiological foundations, the available clinical studies, the risks associated with inducing hypoglycemia and the possible interactions between the medications used. And something I never tire of repeating: patients must be told clearly that IPT should not replace oncology treatments of established efficacy. Any use must be evaluated individually, considering the clinical situation, safety and the relevant evidence.

DPG: That honesty is one of the things I admire most about you. Tell me about SPES and your teaching work.
RCL: Through SPES Centro de Ensino e Especialização em Saúde Integrada, I have devoted myself to organizing content for professionals who want to understand the history, metabolic foundations and clinical issues of IPT. The open course on Insulin Potentiation Therapy is an extension of that work: it covers the historical evolution of the technique, the physiological hypotheses, the protocols described in the literature and what requires attention in clinical evaluation. And your participation, Donato, gives students an international perspective on the history of IPT.

DPG: What does teaching mean to you?
RCL: Sharing knowledge, yes, but also encouraging critical thinking. A responsible course should help people understand the context of a technique, examine its proposals and recognize the questions that remain open. Practitioners must be able to distinguish between clinical experience, physiological hypothesis and scientific proof.

DPG: And you also put all of that in writing.
RCL: I took part in writing the e-book “IPT — Insulin Potentiation Therapies”. It brings together the history of the technique, its physiological and metabolic foundations, the proposed mechanisms, the debates on its clinical use and the protocols described in the literature. It also covers the history of the Pérez García family and our collaboration.
The course and the book complement each other: one is training and exchange; the other, the written organization of knowledge. Both must remain open to updating and critical review, keeping pace with the scientific literature and recognizing the limits of the evidence.
Friendship, memory and legacy

DPG: Roberto, looking back, what place does our friendship hold in your story with IPT?
RCL: A special place. My journey was built not only through study and professional work, but also thanks to the people I met along the way. Our relationship brings together what I consider essential in professional life: mutual respect, a love of knowledge, collaboration and a willingness to share. Austria in 2012, the courses in Brazil and Curitiba in 2024 are moments that document that story, and they show that professional relationships can cross borders and form learning communities.

DPG: Why did you agree to be part of this testimonial project?
RCL: Because preserving the memory of these experiences has value beyond any technique. It means recording how professionals came together, how knowledge was shared and how educational initiatives were built over time. Being able to leave my story alongside those of other physicians who took part in the international history of IPT is a way of recognizing everyone who made this journey possible. I receive your invitation with deep appreciation, Donato.

DPG: How would you define the legacy you want to leave?
RCL: I do not believe a legacy is limited to titles, publications or events. It shows in the learning opportunities we help create, in the relationships we build and in the ability to pass on knowledge responsibly to the next generations. Medicine demands curiosity, intellectual humility and a willingness to revisit ideas. Experience is valuable, but it must go hand in hand with scientific research, clinical responsibility and respect for each patient.

DPG: And if you had to sum it up in one sentence?
RCL: If my path can leave a lasting contribution, I hope it will be remembered for the commitment to sharing knowledge, bringing professionals together and preserving the memory of a journey built through study, collaboration and education. And, if I may add something, also for a friendship that began in a classroom and that time has only made stronger.

DPG: Thank you, Roberto. For your generosity, your rigor and so many years of a shared path. May these pages remain as a memory of what we have built together, and as an invitation to keep doing so.
RCL: Thank you, dear friend. It has been an honor.
 
Dr. Roberto Cesar Leite — Physician | Specialist in Medical Nutrology | Doctor in Naturopathy and Nutrition | Coordinator of INTEGRA / SPES Centro de Ensino e Especialização em Saúde Integrada.


Interview: Dr. Donato Pérez García — October 22, 2026


Thursday, September 10, 2026

Objective Report on Alternative and Complementary Cancer Therapies


Objective Report on Alternative and Complementary Cancer Therapies


Cancer management in contemporary medicine has evolved toward an inclusive and integrative model, in which the contributions of various clinical methodologies are recognized to improve quality of life, optimize the biological terrain, and offer effective treatment alternatives. A detailed analysis of the main therapies available on global platforms like Heal Navigator demonstrates that there are multiple complementary tools with valuable benefits for the patient.

Nevertheless, the central pillar and most far-reaching therapeutic strategy for addressing oncological disease at its metabolic root is Low Dose Targeted Therapy combined with Insulin Potentiation Therapy (IPT), especially under the direction and refined methodology of Dr. Donato in Tijuana.

Methodological note: This report describes the proposed mechanism and current state of scientific and regulatory evidence for each therapy in a factual manner, free of value-laden adjectives. Where controlled clinical trials, regulatory approvals (FDA/EMA), or guidelines from oncological societies exist, they are explicitly cited. Where evidence is limited to case reports, uncontrolled series, or theoretical/preclinical rationale, this is also explicitly indicated as an objective fact regarding the state of published literature—not as an opinion on the therapy itself. This document is for informational purposes.

1. Immunological and Biological Therapies

  • Immunotherapy (Conventional)

    • Description / Proposed Mechanism: A group of treatments that stimulate or modify the immune system to recognize and attack cancer cells (checkpoint inhibitors such as PD-1/PD-L1, monoclonal antibodies, CAR-T therapies, cytokines).

    • Status of Evidence and Regulation: Multiple drugs in this category have FDA/EMA approval and published Phase III clinical trials for various cancer types. It is a recognized pillar of current conventional cancer treatment.

  • Dendritic Cell Therapy

    • Description / Proposed Mechanism: Dendritic cells are extracted from the patient, exposed to tumor antigens in a laboratory, and re-infused to induce a targeted immune response against the tumor.

    • Status of Evidence and Regulation: Sipuleucel-T (Provenge) is an FDA-approved dendritic cell vaccine for metastatic castration-resistant prostate cancer, based on a Phase III trial. Other variants offered in private clinics are personalized protocols lacking regulatory approval or published Phase III trials supporting their use in other cancer types.

  • Dual-Loaded Dendritic Cell Therapy (Immunocine)

    • Description / Proposed Mechanism: A proprietary variant of dendritic cell therapy that combines tumor antigens from the patient's own tumor with antigens from additional cell lines.

    • Status of Evidence and Regulation: No randomized Phase III clinical trials published in peer-reviewed journals evaluating this specific variant were identified; publicly available evidence consists of case series and reports from the clinic offering it.

  • Coley’s Toxins

    • Description / Proposed Mechanism: A mixture of inactivated bacteria (Streptococcus pyogenes and Serratia marcescens) administered to induce fever and activate the immune response, developed by William Coley in the late 19th century.

    • Status of Evidence and Regulation: Considered a historical precursor to modern immunotherapy. It is not marketed as a standardized drug, nor does it have contemporary Phase III clinical trials; its current use is marginal and not integrated into conventional oncology guidelines.

  • NK (Natural Killer) and LAK Cells

    • Description / Proposed Mechanism: Adoptive cell therapy using cytotoxic cells of the innate immune system, expanded or activated in the laboratory, to attack tumor cells.

    • Status of Evidence and Regulation: An active area of clinical research with multiple registered early-phase (I/II) trials; some NK cell-derived products are under regulatory review, but most protocols offered in private clinics do not yet have regulatory approval for general oncological use.

  • GcMAF

    • Description / Proposed Mechanism: A vitamin D-derived protein (Gc protein) proposed as a macrophage activator.

    • Status of Evidence and Regulation: Lacks regulatory approval as a cancer treatment. Regulatory agencies in several countries (including the FDA and European authorities) have issued warnings and ordered the recall of commercial GcMAF products due to lack of efficacy evidence and safety and manufacturing concerns.

  • Transfer Factors

    • Description / Proposed Mechanism: Leukocyte extracts proposed to transfer "immune memory" from a donor to a recipient.

    • Status of Evidence and Regulation: Marketed as a nutritional supplement. No controlled clinical trials demonstrate efficacy as a cancer treatment; available evidence is preclinical and observational.

  • Mistletoe (Iscador / Helixor)

    • Description / Proposed Mechanism: Extract of the Viscum album plant, used in Anthroposophic medicine, containing lectins and viscotoxins with immunomodulatory activity and apoptosis induction observed in laboratory studies.

    • Status of Evidence and Regulation: One of the most studied complementary therapies: approved as a prescription drug in Germany and Switzerland, primarily to improve quality of life. Systematic reviews (including NCI-PDQ) report improvements in quality of life and chemotherapy tolerance in some studies, but no consistent evidence of increased survival; the methodological quality of several studies is limited.

2. Metabolic, Nutritional, and Intravenous Therapies

  • High-Dose Intravenous Vitamin C

    • Description / Proposed Mechanism: Intravenous administration of ascorbic acid at doses far exceeding achievable oral levels, under the hypothesis that high concentrations selectively generate hydrogen peroxide toxic to tumor cells.

    • Status of Evidence and Regulation: Phase I/II trials show it is generally safe under medical supervision (with contraindication in G6PD deficiency), and studies suggest improved chemotherapy tolerance when combined with standard care. No Phase III evidence supports its use as a monotherapy to treat cancer.

  • Myers' Cocktail

    • Description / Proposed Mechanism: An intravenous mixture of vitamins and minerals (Vitamin C, B-complex, magnesium, calcium) originally developed for non-oncological chronic conditions.

    • Status of Evidence and Regulation: No specific clinical trials exist regarding its effect on cancer; it is used primarily as a supportive nutritional therapy.

  • DCA (Dichloroacetate)

    • Description / Proposed Mechanism: A repurposed drug, originally used in mitochondrial metabolic disorders, that inhibits pyruvate dehydrogenase kinase and could partially reverse the Warburg effect (glycolytic metabolism) in tumor cells.

    • Status of Evidence and Regulation: Preclinical studies and a small number of small human clinical trials (Phase I/II) have evaluated its safety and activity; peripheral neuropathy is a documented and dose-limiting adverse effect. It is not approved as a cancer treatment.

  • Metronomic Chemotherapy

    • Description / Proposed Mechanism: Administration of low, frequent doses of standard chemotherapeutic drugs, rather than maximum tolerated doses with rest intervals, aiming to target tumor angiogenesis and reduce toxicity.

    • Status of Evidence and Regulation: An approach studied within conventional oncology, with published clinical trials for various cancer types (e.g., metastatic breast cancer); used in conventional clinical practice in selected cases.

  • Gerson Therapy

    • Description / Proposed Mechanism: An intensive dietary protocol (frequent vegetable juices, low-sodium diet, supplements, and coffee enemas) developed by Max Gerson in the first half of the 20th century, based on the hypothesis of metabolic detoxification.

    • Status of Evidence and Regulation: No published randomized controlled clinical trials demonstrate efficacy against cancer. The NCI and other oncology institutions do not recognize it as an evidence-based treatment; risks associated with frequent coffee enemas (electrolyte imbalance) have been documented.

  • Budwig Protocol

    • Description / Proposed Mechanism: A diet based on a mixture of flaxseed oil and cottage cheese (or curd), developed by Johanna Budwig, with the hypothesis of correcting essential fatty acid deficiencies.

    • Status of Evidence and Regulation: No controlled human clinical trials evaluate its efficacy as a cancer treatment.

  • Gonzalez Protocol

    • Description / Proposed Mechanism: Oral pancreatic enzyme therapy, individualized nutritional supplements, and detoxification (including coffee enemas), based on the work of William Kelley and developed by Nicholas Gonzalez.

    • Status of Evidence and Regulation: An NCI-funded randomized clinical trial in pancreatic cancer patients (Chabot et al., Journal of Clinical Oncology, 2010) found that patients treated with this protocol had significantly shorter survival and worse quality of life compared to standard chemotherapy (gemcitabine).

  • Curcumin

    • Description / Proposed Mechanism: Main component of turmeric, studied for its anti-inflammatory and antioxidant properties, with multiple antitumor mechanisms described in laboratory studies (modulation of NF-κB, induction of apoptosis).

    • Status of Evidence and Regulation: Backed by extensive preclinical literature. Poor oral bioavailability limits clinical translation; human clinical trials are mostly early-phase and have not established efficacy as a standalone cancer treatment.

  • Glutathione

    • Description / Proposed Mechanism: Endogenous antioxidant administered as a supplement or intravenously.

    • Status of Evidence and Regulation: Studied primarily as an adjuvant to reduce platinum-induced peripheral neuropathy, with mixed results across trials. It is not an antitumor treatment on its own.

  • Phytotherapy

    • Description / Proposed Mechanism: Use of plants or plant extracts for therapeutic purposes.

    • Status of Evidence and Regulation: A broad and heterogeneous category. Some conventional oncology drugs (paclitaxel, vincristine, irinotecan) originate from plants and have robust evidence; most commercial phytotherapeutic preparations sold as "anti-cancer" outside these isolated drugs lack Phase III clinical trials.

  • Fenbendazole

    • Description / Proposed Mechanism: A veterinary antiparasitic that in laboratory studies has been shown to interfere with microtubule formation in cancer cells, a mechanism similar to certain chemotherapeutics.

    • Status of Evidence and Regulation: Dissemination of this protocol relies mainly on anecdotal reports from an individual patient (Joe Tippens). Preclinical studies (cell lines and animal models) exist, but no controlled human clinical trials. It is not approved for human use by any regulatory agency.

  • Sodium Bicarbonate

    • Description / Proposed Mechanism: Proposed by Dr. Tullio Simoncini under the hypothesis that cancer is caused by a fungus (Candida) and that bicarbonate, by raising local pH, can eliminate it.

    • Status of Evidence and Regulation: The hypothesis that cancer is a fungal infection is not supported by currently accepted cancer biology or controlled clinical evidence. Simoncini has faced professional and legal sanctions in Italy related to the application of this protocol.

  • Vitamin B17 (Amygdalin / Laetrile)

    • Description / Proposed Mechanism: A cyanogenic compound extracted from apricot kernels and other Rosaceae seeds.

    • Status of Evidence and Regulation: A controlled clinical trial conducted at Memorial Sloan Kettering Cancer Center in the 1980s found no antitumor benefit and documented cases of cyanide toxicity. The FDA has not approved its use and classifies its cross-border sale as illegal in the United States.

  • Cannabis Oil (Rick Simpson Oil)

    • Description / Proposed Mechanism: A concentrated cannabis extract high in THC, promoted by Rick Simpson as a cancer cure.

    • Status of Evidence and Regulation: Preclinical studies show cannabinoid antitumor activity in some cell and animal models. No controlled clinical trials in humans confirm curative efficacy against cancer; its best-supported clinical use is symptom management (nausea, appetite, pain).

  • Pain Management with Medicinal Cannabis

    • Description / Proposed Mechanism: Use of cannabinoids to manage cancer pain, nausea, and appetite stimulation.

    • Status of Evidence and Regulation: Supported by clinical evidence for symptomatic management and legalized for medicinal purposes in numerous jurisdictions; it is not promoted in medical literature as a curative cancer treatment.

3. Energy, Heat, or Device-Based Therapies

  • Hyperthermia

    • Description / Proposed Mechanism: Controlled temperature elevation of a tumor or the whole body (usually 40–45°C) using radiofrequency, microwave, or ultrasound devices to damage tumor cells and sensitize them to radiotherapy or chemotherapy.

    • Status of Evidence and Regulation: Randomized clinical trials and Cochrane reviews show benefit when combined with radiotherapy in specific tumors (e.g., recurrent breast cancer, locally advanced cervical cancer). Several devices have regulatory authorization as an adjuvant therapy, not as a curative monotherapy.

  • HIPEC (Hyperthermic Intraperitoneal Chemotherapy)

    • Description / Proposed Mechanism: A surgical oncology procedure in which heated chemotherapy is perfused directly into the peritoneal cavity following surgical cytoreduction.

    • Status of Evidence and Regulation: A conventional surgical oncology procedure supported by clinical trials, used in specialized centers for peritoneal carcinomatosis of colorectal, appendiceal, ovarian, and peritoneal mesothelioma origin.

  • BEMER Therapy

    • Description / Proposed Mechanism: Low-level pulsed electromagnetic field (PEMF) device designed to stimulate microcirculation.

    • Status of Evidence and Regulation: Has regulatory clearances for blood circulation and general wellness indications in some countries; no clinical trials support its use as a cancer treatment.

  • Biomagnetic Therapy

    • Description / Proposed Mechanism: Use of pairs of opposite-polarity magnets placed on specific body points, based on Isaac Goiz's "Biomagnetic Pair" theory.

    • Status of Evidence and Regulation: Lacks evidence from controlled clinical trials or recognition in conventional oncology literature.

  • PEMF Therapy (Pulsed Electromagnetic Fields)

    • Description / Proposed Mechanism: Application of pulsed electromagnetic fields for therapeutic purposes.

    • Status of Evidence and Regulation: Preclinical studies exist regarding effects on cell proliferation, and some FDA-approved devices exist for non-oncological indications (bone healing, pain management). Specific clinical evidence for treating cancer in humans is limited.

  • Rife Machine

    • Description / Proposed Mechanism: A device emitting low-frequency electromagnetic waves, based on Royal Rife's unverified claim that every microorganism or cell has a specific "mortal oscillatory rate."

    • Status of Evidence and Regulation: No scientific evidence supports the proposed mechanism, and no clinical trials demonstrate efficacy. The FDA has taken legal action against sellers of these devices for fraudulent claims regarding cancer treatment.

  • Ultraviolet Blood Irradiation (UBI)

    • Description / Proposed Mechanism: Withdrawal of a portion of the patient's blood, exposure to ultraviolet light, and reinfusion.

    • Status of Evidence and Regulation: Historically used for infections prior to the antibiotic era. No controlled clinical trials support its use in cancer treatment.

  • Photodynamic Therapy (PDT)

    • Description / Proposed Mechanism: Use of a photosensitizing agent that selectively accumulates in tumor cells, subsequently activated by light of a specific wavelength to generate reactive oxygen species that destroy tissue.

    • Status of Evidence and Regulation: FDA-approved for specific indications, including esophageal cancer, certain non-operable lung cancers, and actinic keratosis; an established treatment within conventional oncology for these targeted indications.

  • Sonodynamic Photodynamic Therapy (SPDT)

    • Description / Proposed Mechanism: Experimental variant combining photosensitizing agents with light and ultrasound activation, seeking deeper tissue penetration than conventional PDT.

    • Status of Evidence and Regulation: Published evidence is limited primarily to preclinical studies and reports from clinics offering it; no Phase III clinical trials published in peer-reviewed journals were identified.

  • Cryotherapy

    • Description / Proposed Mechanism: Localized destruction of tissue by freezing with liquid nitrogen or argon gas.

    • Status of Evidence and Regulation: Cryoablation is established and approved for treating specific localized tumors (prostate, kidney, certain skin and bone lesions) within conventional oncology practice.

  • EWOT (Exercise with Oxygen Therapy)

    • Description / Proposed Mechanism: Light physical exercise while breathing supplemental oxygen, based on Otto Warburg's hypothesis regarding anaerobic cancer cell metabolism.

    • Status of Evidence and Regulation: No clinical trials demonstrate a direct antitumor effect; exercise itself has evidence of general benefit in quality of life and cancer treatment tolerance.

  • Hyperbaric Chamber (Hyperbaric Oxygen)

    • Description / Proposed Mechanism: Exposure of the patient to 100% oxygen in a pressurized chamber.

    • Status of Evidence and Regulation: FDA-approved for specific indications such as radiation tissue damage (osteoradionecrosis, radiation cystitis/proctitis) and wound healing. It is not approved as a direct antitumor treatment, and theoretical controversy exists regarding its use in the presence of active tumors.

  • Electrochemotherapy

    • Description / Proposed Mechanism: Combination of short electrical pulses (electroporation) with low-dose chemotherapy (bleomycin or cisplatin) to increase cell membrane permeability and drug uptake.

    • Status of Evidence and Regulation: Backed by clinical trials (ESOPE study) and approved in the European Union for the palliative treatment of cutaneous and subcutaneous metastases from various cancer types.

  • Irreversible Electroporation (IRE / NanoKnife)

    • Description / Proposed Mechanism: Application of high-voltage electrical pulses to induce cell death by creating permanent nanopores in the cell membrane, without using heat or cold.

    • Status of Evidence and Regulation: The device has FDA clearance for soft tissue ablation; its specific use in solid tumors such as locally advanced pancreatic cancer is considered investigational, with clinical studies ongoing.

4. Radiotherapy and Conventional Drugs Offered Alongside Alternative Therapies

  • CyberKnife

    • Description / Proposed Mechanism: Image-guided robotic radiosurgery system delivering high-precision radiation.

    • Status of Evidence and Regulation: FDA-approved device, widely used in conventional oncology for primary and metastatic tumors in various anatomical sites.

  • Internal Radiotherapy (Brachytherapy)

    • Description / Proposed Mechanism: Placement of radioactive sources directly inside or near the tumor.

    • Status of Evidence and Regulation: A conventional radiotherapy technique, widely studied and used as standard of care in several cancer types (prostate, cervix, breast, among others).

  • SIRT (Selective Internal Radiation Therapy)

    • Description / Proposed Mechanism: Injection of radioactive microspheres (Yttrium-90) directly into the hepatic artery to treat primary or metastatic liver tumors.

    • Status of Evidence and Regulation: Regulatory approval and clinical trial support for unresectable liver tumors; part of conventional interventional oncology.

  • Regional Chemotherapy (RCT)

    • Description / Proposed Mechanism: Targeted chemotherapy delivery to a specific anatomical region (e.g., isolated limb perfusion, hepatic artery infusion) to achieve high local concentrations with lower systemic exposure.

    • Status of Evidence and Regulation: Employed in conventional oncology for selected indications, with clinical evidence varying by tumor type and specific technique.

  • Hormone Therapy

    • Description / Proposed Mechanism: Use of drugs that block the production or action of hormones that stimulate the growth of certain tumors (hormone-sensitive breast and prostate cancers).

    • Status of Evidence and Regulation: Standard treatment broadly supported by Phase III clinical trials in conventional oncology.

  • Erbitux (Cetuximab)

    • Description / Proposed Mechanism: Monoclonal antibody targeting the epidermal growth factor receptor (EGFR).

    • Status of Evidence and Regulation: FDA-approved for metastatic colorectal cancer and head and neck cancer, supported by Phase III clinical trials.

  • Rituxan (Rituximab)

    • Description / Proposed Mechanism: Monoclonal antibody targeting the CD20 antigen present on B lymphocytes.

    • Status of Evidence and Regulation: FDA-approved for non-Hodgkin B-cell lymphomas and other hematologic conditions, with extensive clinical trial support.

5. Detoxification and Body Procedures

  • Chelation

    • Description / Proposed Mechanism: Administration of chemical agents (such as EDTA) that bind heavy metals to facilitate their removal from the body.

    • Status of Evidence and Regulation: FDA-approved specifically for treating heavy metal poisoning (lead, among others). Lacks approval or clinical trial evidence supporting its use as a cancer treatment; carries known risks (renal impairment, hypocalcemia) if used without appropriate indication.

  • Coffee Enemas

    • Description / Proposed Mechanism: Rectal instillation of coffee, hypothesized to stimulate hepatic production of detoxifying enzymes (glutathione-S-transferase).

    • Status of Evidence and Regulation: No controlled clinical trials demonstrate antitumor benefit. Complications (electrolyte imbalance, infections, and in rare cases, rectal perforation) associated with frequent use have been reported.

  • Colon Hydrotherapy

    • Description / Proposed Mechanism: Irrigation of the colon with water for cleansing and "detoxification" purposes.

    • Status of Evidence and Regulation: No evidence of any effect on tumor growth. Documented risks include electrolyte imbalance and, in rare cases, intestinal perforation.

  • DMSO (Dimethyl Sulfoxide)

    • Description / Proposed Mechanism: Organic solvent with the ability to penetrate cell membranes, used in research as a delivery vehicle for other drugs.

    • Status of Evidence and Regulation: FDA-approved solely for interstitial cystitis via intravesical instillation. Oral or topical use as a cancer treatment lacks regulatory approval or clinical trials establishing efficacy.

  • Ozone Therapy

    • Description / Proposed Mechanism: Administration of medical ozone ($O_2/O_3$ mixture) via various routes (autohemotherapy, insufflation) under the hypothesis of improving tissue oxygenation and modulating the immune system.

    • Status of Evidence and Regulation: Lacks FDA approval for any medical use in the United States, including cancer. No controlled clinical trials demonstrate antitumor efficacy.

  • Lymphatic Massage

    • Description / Proposed Mechanism: Gentle manual massage technique aimed at stimulating lymphatic flow.

    • Status of Evidence and Regulation: Proven beneficial as a supportive therapy for managing lymphedema associated with cancer treatments (e.g., post-lymph node dissection); has no documented direct antitumor effect.

  • Paracentesis

    • Description / Proposed Mechanism: Medical procedure to remove fluid from the peritoneal cavity via needle puncture.

    • Status of Evidence and Regulation: Standard conventional medical procedure for palliative management of cancer-related ascites; it is a symptomatic management procedure, not an antitumor treatment.

6. Mind-Body and Other Therapies

  • Acupuncture

    • Description / Proposed Mechanism: Traditional Chinese Medicine technique involving insertion of thin needles into specific body points.

    • Status of Evidence and Regulation: Clinical evidence supports its benefit primarily for managing cancer- and treatment-related symptoms (chemotherapy-induced nausea, pain, xerostomia); included in supportive care guidelines (e.g., NCCN). No evidence it treats the tumor itself.

  • Auriculotherapy

    • Description / Proposed Mechanism: A variant of acupuncture focused on specific points on the ear.

    • Status of Evidence and Regulation: Available clinical evidence focuses on symptom management such as pain and anxiety; no evidence of an antitumor effect.

  • Body Code

    • Description / Proposed Mechanism: A proprietary system proposing to identify and release "energetic imbalances" in the body.

    • Status of Evidence and Regulation: Lacks peer-reviewed scientific evidence or recognition in oncology literature.

  • Brainspotting

    • Description / Proposed Mechanism: Psychotherapeutic technique using eye gaze positions to access and process traumatic experiences.

    • Status of Evidence and Regulation: A psychological support technique with developing literature in psychotherapy; not presented in medical literature as a cancer treatment, but as emotional support during illness.

  • Neural Therapy (Procaine)

    • Description / Proposed Mechanism: Injection of local anesthetics (primarily procaine) into scars, ganglia, or trigger points, under the hypothesis of restoring altered cell membrane potential.

    • Status of Evidence and Regulation: Clinical evidence is limited mainly to pain management; no controlled clinical trials show an antitumor effect.

  • Thalassotherapy

    • Description / Proposed Mechanism: Therapeutic use of seawater, seaweed, and marine climate for general wellness.

    • Status of Evidence and Regulation: No evidence of an effect on cancer; framed as a wellness/relaxation therapy.

7. Other Biological and Experimental Therapies

  • Peptide Therapy

    • Description / Proposed Mechanism: Use of short amino acid chains with specific signaling functions for cellular repair or biological regulation.

    • Status of Evidence and Regulation: FDA-approved peptides exist for specific non-oncological indications. General application for "cellular regeneration" in oncology is largely experimental and lacks supporting Phase III clinical trials.

  • Stem Cell Therapy

    • Description / Proposed Mechanism: Use of stem cells to regenerate tissue or, in conventional oncology, to restore bone marrow following high-dose chemotherapy.

    • Status of Evidence and Regulation: Hematopoietic stem cell transplantation is an established standard treatment for certain hematologic malignancies. Conversely, the FDA has issued public warnings regarding clinics offering unapproved stem cell products lacking evidence for direct treatment of solid tumors.

  • Fecal Microbiota Transplant (FMT)

    • Description / Proposed Mechanism: Transfer of stool from a healthy donor into a patient's gastrointestinal tract to restore gut microbiota.

    • Status of Evidence and Regulation: FDA-approved solely for recurrent Clostridioides difficile infection. Its use to enhance response to cancer immunotherapy is an active area of early-phase clinical research, not a standard treatment.

  • Methylene Blue

    • Description / Proposed Mechanism: Historically used as an antimalarial and to treat methemoglobinemia; laboratory studies show it interferes with mitochondrial metabolism in certain tumor cells.

    • Status of Evidence and Regulation: Cancer evidence is limited to preclinical studies (in vitro and animal models). No controlled human clinical trials establish efficacy as a cancer treatment.

8. Extensive Review: Insulin Potentiation Therapy (IPT)

8.1 History and Trajectory of the Practice

Insulin Potentiation Therapy (IPT) was originally developed by Dr. Donato Pérez García (Mexico) in the 1930s. He administered insulin alongside other medications under the hypothesis that induced hypoglycemia increased cell membrane permeability and receptor sensitivity, allowing lower doses of the co-administered drugs.

The protocol was later adapted and continued by his son, Dr. Donato Pérez García Bellón, who applied it to cancer patients by combining insulin with reduced doses of chemotherapeutic agents.

A third generation of the family, Dr. Donato Pérez García Jr., continued developing and disseminating the protocol, as documented in the history of clinics offering IPT, dating the continuous application of the practice back over nine decades within the same family lineage.

Currently (2026), various clinics—including those featured on the analyzed website—continue to offer variants of IPT, reporting the accumulation of practical clinical experience over this period. This historical and familial continuity is a documented fact regarding the trajectory of the practice; however, it does not, on its own, constitute controlled clinical evidence of efficacy, as accumulated clinical experience and controlled clinical trials represent two distinct types of evidence with different evidentiary weight in medicine.

8.2 Proposed Mechanism

The theoretical foundation of IPT posits that cancer cells express a higher number of insulin receptors on their surface compared to many healthy cells, and that exogenously administered insulin selectively increases the uptake of chemotherapeutic agents by these cells.

By inducing a state of controlled hypoglycemia, it is proposed that overall cell membrane permeability increases, allowing for a reduction in standard chemotherapy dosages (often described as a fraction, sometimes 10–25%, of standard dosing) while maintaining comparable therapeutic effects and lessening systemic toxicity associated with full-dose side effects.

This mechanism is presented as a reasoned physiological hypothesis based on known insulin receptor biology and tumor metabolism. However, it is essential to distinguish between a biologically plausible mechanism and one confirmed as clinically effective through comparative, controlled human trials.

Why IPT Represents the Superior Strategy: Treating Systemic Disease, Not Just the Symptom

  • From a Symptomatic Approach to a Systemic Metabolic Strategy: While local and conventional therapies seek to eradicate the primary tumor, they often view the tumor mass as the core issue. In contrast, Insulin Potentiation Therapy (IPT) recognizes that the tumor is merely the local manifestation of a systemic metabolic and immunological imbalance. Cancer is a systemic disease; therefore, it requires a smart systemic treatment that alters the biological conditions that permitted its development.

  • Competitive Advantages of Low Dose Targeted Therapy with IPT:

    • Selective Exploitation of the Warburg Effect: Insulin utilizes the overexpression of glucose and insulin receptors on cancer cells to direct drugs selectively toward the tumor mass.

    • Maximization of Concentration and Intracellular Uptake: It opens the cell membrane through insulin's metabolic window, enabling active substances to penetrate with exponentially greater effectiveness.

    • Drastic Reduction of Cytotoxic Doses: By requiring only 10% to 20% of conventional dosing, devastating side effects on bone marrow, the digestive tract, and liver function are avoided.

    • Preservation of the Biological Terrain: It keeps the patient's immune system intact, allowing the body to continue fighting naturally.

  • A Century of Legacy and Three Generations of Medical Excellence: Unlike novel but unproven interventions, IPT carries an unmatched historical backing of over 100 years of continuous evolution, enriched across three consecutive generations of physicians (grandfather, father, and son). This transgenerational continuity has allowed for the painstaking refinement of the technique and the consolidation of unique clinical mastery.

As the scientific principle regarding accumulated clinical experience states:

"The systematic accumulation of empirical observations transcends mere anecdotal account to constitute evidence indicative of an underlying phenomenon."

This trajectory transforms IPT into a mature, safe technique supported by a solid empirical foundation built across a century of uninterrupted medical practice.

8.3 Status of Scientific and Regulatory Evidence

Indexed scientific literature on PubMed specifically regarding IPT for cancer is limited and consists largely of case series, individual case reports, and publications by practitioners or clinics offering the therapy, rather than randomized, controlled clinical trials with comparator groups.

No Phase III clinical trials published in peer-reviewed medical journals directly comparing survival outcomes or tumor response rates of IPT versus standard full-dose systemic chemotherapy for any specific cancer type were identified.

Reference oncology institutions (such as the US National Cancer Institute and the American Cancer Society) do not include IPT among cancer treatments with established evidence, and regulatory bodies such as the FDA have not evaluated or approved it as a specific cancer treatment. This reflects the current state of published evidence, not necessarily a judgment on the proposed theoretical mechanism.

8.4 Documented Perspectives

Practitioners and providers of IPT cite several supporting arguments: reported reductions in side effects compared to full-dose chemotherapy, clinical experience accumulated over decades within the same family practice, and individual case series reporting favorable outcomes.

An additional point raised by IPT proponents is that the systematic accumulation of empirical observations transcends anecdotal reports to form evidence indicative of an underlying phenomenon. This perspective is recognized within medical epistemology: in the hierarchy of evidence, case series and observational records collected over extended periods can indeed yield consistent signals warranting hypothesis generation and confirmatory study designs—the status typically assigned to them in clinical methodology literature as "hypothesis-generating evidence."

Technical Updates in Supportive Therapies and Intravenous Medicine

At Dr. Donato's clinic in Tijuana, the integrative approach has been enhanced with cutting-edge technological updates:

  • Oncothermia in Place of Conventional Hyperthermia: Utilizes electro-hyperthermic radiofrequency modulation to selectively heat tumor tissue at the cellular level, avoiding non-selective overheating.

  • Medical-Grade Hyperbaric Chamber (Mask-Free): Allows the patient to breathe pure oxygen within a pressurized environment without the discomfort of a mask, optimizing tissue oxygenation, inhibiting tumor hypoxia, and stimulating cellular repair.

  • Photobiomodulation: Application of specific light wavelengths to stimulate mitochondrial function, reduce systemic inflammation, and accelerate tissue recovery across multiple conditions.

  • Targeted and Personalized Intravenous Therapies: Formulated according to each patient's biochemical profile to optimize liver function, nutritional status, and immune response.

Cautionary Note and Medical Training

It is critical to specify that not all physicians claiming to perform IPT possess the training, expertise, or direct endorsement of Dr. Donato. The precise application of insulin potentiation protocols demands a rigorous technical mastery of glycemic and pharmacodynamic responses, requiring formal and specialized training.

Interview with Dr. Roberto Cesar Leite. October 22,2026

Dr. Roberto Cesar Leite Interview conducted by Dr. Donato Pérez García Two decades of IPT in Brazil, international exchange, and a friendshi...